# 24-Month Implementation Timeline (Executive Roadmap)

## Overview
This roadmap provides a 24-month, milestone-focused plan from MVP to Thai FDA submission and commercialization. It includes go/no-go gates at Months 3, 6, 12, and 18 with explicit success criteria.

## Gantt-Style Table
| Phase | Months | Key Activities | Output |
| --- | --- | --- | --- |
| Phase 1: MVP + Partner MOU | 1-6 | Partner negotiation, pilot readiness, go/no-go decision | Signed MOU |
| Phase 2: QMS + Clinical Protocol | 7-12 | ISO 13485 prep, IRB approval | Trial ready to launch |
| Phase 3: Clinical Trial + FDA Prep | 13-18 | Data collection, final analysis | Clinical evidence package |
| Phase 4: FDA Submission + Scale | 19-24 | FDA submission, commercialization | Approval + customers |

## Phase Details
### Phase 1 (Month 1-6): MVP + Partner MOU
- Month 1-2: Partner negotiation and scope alignment.
- Month 3-4: Pilot readiness (workflow mapping, disclosures, SOPs).
- Month 5-6: Go/no-go decision and pilot approval.
- Output: Signed MOU with pilot partners.

### Phase 2 (Month 7-12): QMS + Clinical Protocol
- Month 7-9: ISO 13485 preparation and QMS documentation.
- Month 10-12: IRB submission and approval.
- Output: Trial ready to launch.

### Phase 3 (Month 13-18): Clinical Trial + FDA Prep
- Month 13-18: Data collection (6 months).
- Month 18: Final analysis and evidence package.
- Output: Clinical evidence package for CSDT.

### Phase 4 (Month 19-24): FDA Submission + Scale
- Month 19-20: FDA submission and response handling.
- Month 21-24: Commercialization and early customer rollout.
- Output: Approval + initial customers.

## Go/No-Go Gates and Success Criteria
| Gate | Timing | Success Criteria |
| --- | --- | --- |
| Gate 1 | Month 3 | MVP stability, safety validation, pilot scope agreed |
| Gate 2 | Month 6 | MOU signed, pilot staffing and escalation SLA confirmed |
| Gate 3 | Month 12 | IRB approval, QMS readiness confirmed |
| Gate 4 | Month 18 | Trial outcomes meet primary endpoint, evidence complete |

## Key Outputs by Gate
- Month 3: MVP validation report and pilot SOPs.
- Month 6: Signed MOU and pilot readiness checklist.
- Month 12: IRB approval and QMS documentation set.
- Month 18: Clinical evidence package and draft CSDT dossier.

## Next Steps
- Confirm partner sites and governance owners.
- Align funding plan with Phase 2 and Phase 3 milestones.
